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Centre for Urology Research, Faculty of Health Sciences & Medicine, Bond University, Gold Coast, QLD, Australia
Current pharmacological treatment options for many bladder contractile dysfunctions
are not suitable for all patients, thereby bringing interest to the investigation of therapies
that target a combination of receptors. This study aimed to compare responses of PGE2
on the urinary bladder urothelium with lamina propria (U&LP, also called the bladder
mucosa) or detrusor smooth muscle and attempt to identify the receptor subtypes
mediating PGE2 contractile responses in these tissues. In the presence of selective
EP1 – 4 receptor antagonists, varying concentrations of PGE2 were applied to isolated
strips of porcine U&LP and detrusor that were mounted in organ baths filled with Krebs-
bicarbonate solution and gassed with carbogen. The addition of PGE2 (1 and 10 µM)
and PGF2α (10 µM) to U&LP preparations caused significant increases in the baseline
tension and in the spontaneous phasic contractile frequency. In detrusor preparations,
significant increases in the baseline tension were observed in response to PGE2 (1 and
10 µM) and PGF2α (10 µM), and spontaneous phasic contractions were initiated in
83% of preparations. None of the selective PGE2 receptor antagonists inhibited the
increases in baseline tension in both U&LP and detrusor. However, the antagonism of
PGF2α receptor showed significantly inhibited contractile responses in both layers of
the bladder. This study presents prostaglandin receptor systems as a potential regulator
of urinary bladder contractility. The main contractile effects of PGE2 in both U&LP and
detrusor are mediated via the FP receptor with no observed contribution from any of the
four EP receptors.
Keywords: inflammatory mediators, prostaglandins, prostaglandin antagonists, urinary bladder, overactive
bladder, bladder inflammation, urothelium, mucosa
Abbreviations: ATP, adenosine triphosphate; OAB, overactive bladder; PGE2, prostaglandin E2; PGF2α, prostaglandin
F2α; SEM, standard error of the mean; U&LP, lamina propria with urothelium; UAB, underactive bladder; αβm-ATP,
α,β−methylene ATP.
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INTRODUCTION
Bladder contractile dysfunctions, such as overactive bladder
(OAB) and underactive bladder (UAB), are common lower
urinary tract dysfunctions that lower the overall quality of life
in people living with it (Haylen et al., 2010; D’ancona et al.,
2019), heightens the likelihood of developing depression and
anxiety, as well as increase healthcare usage (Milsom et al.,
2012). Despite extensive research investigating the mechanisms
that potentially mediate bladder contractions, the cause and
development of many lower urinary tract dysfunctions are poorly
understood. Bladder contractions are under the control of the
parasympathetic nervous system (De Groat et al., 1981) and
mediated by the release of acetylcholine that acts upon the M2
and M3 muscarinic receptors found in the detrusor smooth
muscle (Hegde et al., 1997; Sigala et al., 2002). It has been
recognized that the urothelium, which lines the lumen of the
bladder, is capable of responding to mechanical, chemical and
thermal stimuli (Birder, 2006; Stromberga et al., 2019, 2020b).
Furthermore, it is capable of releasing several signaling molecules
in response to stretch, including acetylcholine (Moro et al., 2011)
ATP and nitric oxide (Ferguson et al., 1997; Fry and Vahabi,
2016) that are involved in the modulation of the micturition
reflex. Myofibroblasts (also referred to as interstitial cells) found
in the underlying lamina propria are thought to be involved in
modulating bladder behavior by amplifying sensory responses
to stretch occurring during the filling phase (Fry et al., 2007).
Therefore, the involvement of the urothelium and the underlying
lamina propria should be considered as potential contributors to
bladder contractile pathology.
Prostaglandins have been suggested to be involved in the
modulation of bladder function for decades. They are synthesized
from arachidonic acid that is released from the cell membrane via
the hydrolysis of the SN-2 bond by the phospholipase A2 enzyme
(PLA2) (Clark et al., 1991). Prostaglandins can also be produced
locally within the U&LP and smooth muscle layers in the
human urinary bladder (Abrams et al., 1979; Jeremy et al., 1987).
Two cyclooxygenase isoforms COX-1 and COX-2 metabolize
arachidonic acid into PGH2, which is subsequently converted
into five primary prostaglandins via their respective synthases:
PGE2, PGD2, PGF2α, PGI2 and TXA2 (Woodward et al.,
2011). These signaling molecules exert their function through
the stimulation of nine specific G-protein coupled receptors
(GPCRs): EP1–EP4, DP1, DP2, FP2, IP, and TP, respectively. Both
COX-1 and COX-2 are expressed within the bladder wall (De
Jongh, 2007, 2009) specifically on the urothelium, lamina propria
and on the surface of the inner muscle bundles of the detrusor.
COX-1 is predominately expressed in the basal and intermediate
layers of the urothelium and on the interstitial cells located in
the lamina propria, indicating that these cells are capable of
respond to prostaglandins (De Jongh, 2009). The production of
prostaglandins differs between species. For example, in the rat
bladder, PGI2 is the major prostaglandin produced (Jeremy et al.,
1984), whereas in the rabbit bladder it is PGE2 (Leslie et al., 1984).
In the human bladder, the primary prostaglandins synthesized are
PGI2, followed by PGE2, PGF2α, and TXA2 (Jeremy et al., 1984;
Masunaga et al., 2006). However, there are significant differences
in the bladder contractile responses between species for the
different prostaglandin receptor subtypes (Root et al., 2015).
Studies involving human detrusor have shown that the release
of prostaglandins has direct influences on the micturition reflex
(Bultitude et al., 1976; Andersson et al., 1977). Overproduction
of prostaglandins have been observed in several conditions,
including bladder outlet obstruction (Masick et al., 2001),
bladder overactivity due to spinal cord injury (Masunaga et al.,
2006), and in inflammation (Wheeler et al., 2001). Furthermore,
contractions of the detrusor smooth muscle in response to
acetylcholine and ATP are enhanced by prostaglandins in
both rabbit (Anderson, 1982) and guinea-pig animal models
(Nile et al., 2010). There are complex interactions between
the three chemicals, as ATP enhances PGE2 release via a P2-
purinoreceptor-mediated mechanism (Kasakov and Vlaskovska,
1985), and acetylcholine is a modulator of PGE2 release (Nile
and Gillespie, 2012). The interactions between these mediators
can potentially result in amplification of molecule signaling and
therefore in increased contractile activity, further supporting the
interest in investigating prostaglandin involvement in contractile
disorders such as OAB. Other research has also shown interest in
prostaglandin release from the lower urinary tract. For example,
the presence of PGE2 in the urine has been linked to bladder
dysfunction and proposed as a potential future biomarker (Reyes
and Klahr, 1990). To further this, urine samples collected
from female patients with overactive bladder showed that there
were significant increases in the PGE2 and PGF2α levels when
compared with the control group (Kim et al., 2006).
Prostaglandin E2, in particular, is thought to be the most
likely contributor to bladder disorders as it can modulate bladder
function via afferent signaling (Andersson, 2010) and potentially
detrusor overactivity by sensitizing capsaicin-sensitive afferent
nerve endings (Maggi, 1988; Park et al., 1999). It is released upon
degranulation of mast cells (Schmauder-Chock and Chock, 1989)
together with histamine, which is also capable of impacting the
bladder contractility (Stromberga et al., 2019, 2020a). Moreover,
PGE2 is produced locally in the bladder in response to distension
and inflammation (Funk, 2001). Notably, the excitatory effects
exerted on the bladder wall via the stimulation of PGE2
receptors has previously been studied in the rat (Chuang et al.,
2012) and mouse (Schroder et al., 2004; Mccafferty et al.,
2008) animal models. There are four identified prostaglandin
E2 receptor subtypes: EP1, EP2, EP3, and EP4. The presence
of the EP1 and EP2 receptor subtypes has been shown in
guinea pig urothelium and lamina propria (Rahnama’i et al.,
2010) and the expression of all four PGE2 receptor subtypes
(EP1–EP4) has been identified in the canine bladder using
in situ hybridization and immunohistochemistry (Ponglowhapan
et al., 2010). Generally, activation of EP1 and EP3 receptors is
associated with an excitatory response, whereas EP2 and EP4
are associated with inhibition of smooth muscle contractility
(Woodward et al., 2011). Furthermore, clinical uses of the
prostaglandin E2 agonist dinoprostone, include the stimulation
of uterine smooth muscle contractions during labor (Stephenson
and Wing, 2015) with the prostaglandin F2α agonist, carboprost,
being a viable alternative to oxytocin during the management
of labor (Sunil Kumar et al., 2016). Therefore, the involvement
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of EP1, EP3 and FP receptors is of particular interest in the
modulation of lower urinary tract contractility due to their
excitatory effect when stimulated.
Alterations in bladder physiology in disease states has
been thought to primarily occur through the regulation of
detrusor smooth muscle contractility. However, it is increasingly
recognized that the bladder urothelium with lamina propria
(U&LP, also called the bladder mucosa) plays an important role
in the overall contractility of the bladder and in its intracellular
signaling. As such, recent research has focused on the effects of
pharmacological mediators on the physiology of the U&LP and
the detrusor as separate layers. This study aimed to compare
responses of the urothelium with lamina propria to PGE2
with those of the detrusor and identify the receptor subtypes
responsible for the PGE2-mediated contractions in these tissues.
MATERIALS AND METHODS
Tissue Preparation
Urinary bladders were obtained from female Large-White-
Landrace pigs (approximately 6 months old, with a live-weight of
80–100 kg) from the local abattoir after slaughter for the routine
commercial provision of food. Isolated strips (10 mm × 5 mm)
of porcine bladder were removed from the anterior wall of
the bladder dome region and urothelium with lamina propria
(U&LP) carefully dissected from the underlying detrusor layer.
Two adjacent strips were taken from each animal’s bladder and
paired together as control-experimental tissues, with each paired
strip preparation expressed as “n” where comparisons or changes
are recorded. n equates to the number of individual bladders
used in this study.
Strips of U&LP and detrusor tissue were suspended in 10 mL
organ baths (Labglass, Brisbane, QLD, Australia) containing
Krebs-bicarbonate solution (NaCl 118.4 mM, NaHCO3 24.9 mM,
CaCl2 1.9 mM, MgSO4 2.41 mM, KCl 4.6 mM, KH2PO4 1.18 mM,
and D-glucose 11.7 mM) at 37◦C and perfused with a gas mixture
of 95% oxygen and 5% carbon dioxide. The preparations were
washed three times with Krebs-bicarbonate solution and tension
adjusted to approximately 2 g, which then became the tissue
baseline. A single dose of agonist was added to the U&LP
and detrusor preparations after an incubation period with an
antagonist or vehicle control. The concentrations specific for each
receptor subtype were determined using affinity values appearing
in the literature utilizing similar methodology and isolated tissue
bath experiments. Tissue strips exposed to antagonists or vehicle
controls were incubated for 30 min to allow full equilibration
with the receptor. Each experiment was completed within 20 min
after the addition of the agonist. Baseline tension, frequency
and amplitude of spontaneous phasic contractions were recorded
simultaneously using isometric force transducers (MCT050/D,
ADInstruments, Castle Hill, NSW, Australia) on a PowerLab
system using LabChart v7 software (ADInstruments). Porcine
urinary bladders are a well-recognized animal model for bladder
research (Cheng et al., 2011; Parsons et al., 2012; Mitsui et al.,
2019; Stromberga et al., 2019) with similar physiology and
pharmacology to human bladders. As no animals were bred,
harmed, culled, interfered, or interacted with as part of this
research project, Animal Ethics Approval was not required for
bladder use (Queensland Government, 2016).
Pharmaceutical Agents
Prostaglandin E2, F2α, EP1 receptor antagonist SC-19220, EP1,
and EP2 receptor antagonist AH6809, EP3 receptor antagonist
L-798106, EP4 receptor antagonist AH23848, FP receptor
antagonist AL-8810 and ATP receptor agonist α,β-methylene
ATP were obtained from Cayman Chemicals, Ann Arbor, MI,
United States. The muscarinic receptor antagonist atropine,
cyclooxygenase (COX) inhibitor indomethacin, and the nitric
oxide synthase inhibitor Nω-Nitro-L-arginine were obtained
from Sigma Aldrich, St. Louis, MO, United States. Prostaglandin
E2, prostaglandin F2α, AH6809 and indomethacin were dissolved
in 100% ethanol and diluted as needed with distilled H2O.
Atropine, Nω-Nitro-L-arginine, and α,β-methylene ATP were
dissolved in distilled H2O and diluted as required. SC19220, L-
798196, AH23848, and AL-8810 were dissolved in DMSO and
diluted with distilled H2O.
Experimental Procedure
A single dose of prostaglandin E2 (1 or 10 µM) or prostaglandin
F2α (10 µM) was applied to an isolated strip of U&LP or detrusor
after a 30-minute equilibration period with a selective receptor
antagonist. Baseline tensions and the amplitude and frequency
of spontaneous phasic contractions of U&LP were measured
before the application of the agonist and 5 min after addition.
As spontaneous contractions were only observed in 21% of
detrusor samples, only baseline tension was measured (before the
application of the agonist, 10 min after and 20 min after).
Measurements and Statistical Analysis
The changes in the baseline tension were measured before the
addition of an agonist and at the peak contractile response.
The frequency of spontaneous contractions was measured over
a period of 5 min and expressed as the number of spontaneous
phasic contraction cycles per minute (cpm). The average
amplitude was measured from base to peak of each spontaneous
contraction. Measurements for frequency and amplitude were
taken before any agonist was added and during the peak
contractile response to the agonist. Data was graphed and
analyzed using GraphPad Prism version 8.1.1 for Windows
(GraphPad Software, La Jolla, CA, United States) and results
shown as the mean change ± SEM. Responses between control
and experimental tissues were compared using a Student’s t-test
with p< 0.05 considered significant.
RESULTS
Prostaglandin E2 on U&LP Preparations
In the absence of prostaglandin E2 or any receptor antagonists,
strips of urothelium with lamina propria (U&LP) exhibited
spontaneous phasic contractions at frequencies of 3.34 ± 0.06
cycles per min−1 (cpm) with amplitudes of 0.52± 0.02 g (n = 215
for both). In response to prostaglandin E2 (1µM), U&LP baseline
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TABLE 1 | U&LP effect of prostaglandin E2 (1 and 10 µM) on the baseline tension
and on the frequency and amplitude of spontaneous phasic contractions (mean
change ± SEM).
PGE2 conc. 1Tension (g) 1Frequency (cpm) 1Amplitude (g) n
1 µM 1.01 ± 0.08*** 1.13 ± 0.19*** −0.14 ± 0.04*** 38
10 µM 1.36 ± 0.09*** 1.19 ± 0.30** −0.16 ± 0.03** 42
**p < 0.05, ***p < 0.001. Paired Student’s two-tailed t-test.
tensions increased by 91± 9% (n = 38, p< 0.001), the frequency
of spontaneous phasic contractions increased by 39± 7% (n = 38,
p < 0.001) and amplitudes decreased by 18 ± 5% (n = 38,
p < 0.001) during the peak response (Table 1 and Figure 1).
The addition of an even higher concentration of prostaglandin
E2 (10 µM) caused increases in the U&LP baseline tensions by
106 ± 9% (n = 42, p < 0.001), frequencies of spontaneous phasic
contractions by 40 ± 10% (n = 42, p < 0.01) and amplitude
decreases by 28 ± 6% (n = 22, p < 0.001) during peak response
(Table 1 and Figure 1).
Prostaglandin E2 on Detrusor
Preparations
In detrusor preparations, PGE2 caused concentration-dependent
increases in baseline tension over the increasing concentrations
(1–10 µM, Table 2 and Figure 2). Detrusor preparations did not
reach a visible peak in response to PGE2 within the experimental
timeframe, so each tension recording was completed at set
intervals of 10 and 20 min. In response to prostaglandin E2
(1 µM, Table 2 and Figure 2), an increase of 80 ± 13% (n = 38,
p < 0.001) was observed 10 min after the addition of the agonist,
and in response to prostaglandin E2 (10 µM, Table 2 and
Figure 2) an increase of 155 ± 21% (n = 34, p < 0.001) was
observed 10 min after the addition of agonist. Twenty minutes
after the addition of prostaglandin E2 (1 µM, Table 2), baseline
tensions had increased by 107± 13% (n = 38, p< 0.001), whereas
20 min after the treatment with prostaglandin E2 (10 µM,
Table 2), had increased by 175± 21% (n = 34, p< 0.001).
Only 21% of all detrusor preparations exhibited spontaneous
phasic contractions at baseline and as such, the frequency
and amplitude of spontaneous activity was not calculated. Of
TABLE 2 | Detrusor effect of prostaglandin E2 (1 and 10 µM) on the baseline
tension and on the frequency and amplitude of spontaneous phasic contractions
(mean change ± SEM).
PGE2 conc. 1Tension (g) at 10 min 1Tension (g) at 20 min n
1 µM 0.77 ± 0.09*** 1.06 ± 0.09*** 38
10 µM 1.34 ± 0.14*** 1.46 ± 0.11*** 34
***p < 0.001. Paired Student’s two-tailed t-test.
those that did not exhibit baseline activity, spontaneous phasic
contractions were initiated after the addition of PGE2 in 83%
of preparations.
Receptor-Selective Antagonists in U&LP
Preparations
The responses to prostaglandin E2 were observed in the presence
of the selective receptor antagonists: SC-19220 (EP1 antagonist,
10 µM), AH6809 (EP1/EP2 antagonist, 10 µM), L-798106 (EP3
antagonist, 100 nM) and AH23848 (EP4 antagonist, 10 µM).
None of the prostaglandin E2 receptor antagonists had any effect
on baseline tension, frequency or amplitude of spontaneous
phasic contractions and they also had no effect on U&LP in
response to prostaglandin E2 (1 µM, Table 3). The time required
to reach peak baseline tension was investigated in U&LP tissues
treated with PGE2 in the presence and absence of EP receptor
antagonists. In response to prostaglandin E2 (1 µM), U&LP
tissue strips took 4.48 ± 0.28 min to reach their peak baseline
tensions. Tissues incubated with SC-19220 (1µM, n = 8, p< 0.05)
took 6.37 ± 0.39 min to reach peak. There were no significant
differences in times taken to reach peak baseline tension in tissues
treated with either AH6809, L-798106 or AH23848.
The potential influence of receptor systems, other than
prostaglandin E2, to contribute contractile responses to PGE2
were investigated. Neither the baseline tension, frequency nor
amplitude of spontaneous phasic contractions in response to
prostaglandin E2 (10 µM) were affected by the presence of the
muscarinic receptor antagonist atropine (1 µM), cyclooxygenase
(COX) inhibitor indomethacin (5 µM), nitric oxide synthase
inhibitor Nω-Nitro-L-arginine (L-NNA, 100 µM) or P2X
receptor desensitizing agonist α,β-methylene ATP (αβm-ATP,
FIGURE 1 | Traces showing changes to baseline tension of U&LP in response to PGE2 at concentrations of 1 µM (A) and 10 µM (B) over 15 min. (C) Peak
responses after the addition of PGE2 (1 µM, n = 38) and PGE2 (10 µM, n = 42).
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FIGURE 2 | Traces showing changes to baseline tension of detrusor smooth muscle in response to PGE2 at concentrations of 1 µM (A) and 10 µM (B) over 15 min.
(C) Peak responses after the addition of PGE2 (1 µM, n = 38) and PGE2 (10 µM, n = 34).
TABLE 3 | Baseline tension and phasic contraction responses to U&LP treatment with prostaglandin E2 (1 µM) in the absence and presence of prostaglandin E2
receptor antagonists (mean change ± SEM).
1Tension (g) 1Frequency (cpm)
Antagonist Conc. Absence Presence Absence Presence n
SC-19220 10 µM 1.01 ± 0.19 1.27 ± 0.24 1.32 ± 0.43 1.88 ± 0.38 8
AH6809 10 µM 1.12 ± 0.19 1.14 ± 0.20 1.42 ± 0.53 1.23 ± 0.41 8
L-798106 100 nM 0.97 ± 0.09 0.82 ± 0.10 0.68 ± 0.15 0.80 ± 0.18 8
AH23848 10 µM 0.90 ± 0.10 0.99 ± 0.13 1.05 ± 0.36 1.61 ± 0.44 12
None of the antagonists had statistically significant effects using a paired Student’s two-tailed t-test.
10µM, Table 4). The tissue did not exhibit changes in the tension
or in the frequency of phasic contractions in response to the
addition of the FP receptor antagonist AL-8810 (5µM). However,
the presence of AL-8810 (5 µM) significantly inhibited increases
in the baseline tension in response to PGE2 (10 µM, n = 8,
p< 0.05, Figure 3). In the absence of any antagonist, contractions
to PGE2 increased the tension by 103 ± 12%. In the presence of
AL-8810 (5 µM) this increase was inhibited with the remaining
contraction being 77± 8% (n = 8, p< 0.05, Table 4).
Receptor-Selective Antagonists in
Detrusor Preparations
Detrusor preparations did not reach a visible peak in response
to PGE2 (1 µM) within the experimental timeframe, so each
tension recording was completed at set intervals of 10 and 20 min.
As such, changes in detrusor tension were measured at 10 and
20 min after the addition of each agonist (Table 5). The responses
to prostaglandin E2 were observed in the presence of the
selective prostaglandin E2 receptor antagonists: SC-19220 (EP1
antagonist, 10 µM), AH6809 (EP1/EP2 antagonist, 10 µM), L-
798106 (EP3 antagonist, 100 nM) and AH23848 (EP4 antagonist,
10 µM). None of the prostaglandin E2 receptor antagonists had
any effect on baseline tension in detrusor tissue strips in response
to prostaglandin E2 (1 µM).
The potential for receptor systems, other than prostaglandin
E2, to contribute contractile responses to PGE2 were investigated.
It was found that the baseline tension in detrusor preparations,
in response to prostaglandin E2 (10 µM), was not affected by
the presence of the muscarinic receptor antagonist atropine
(1 µM), cyclooxygenase (COX) inhibitor indomethacin (5 µM),
nitric oxide synthase inhibitor Nω-Nitro-L-arginine (L-NNA,
100 µM) or P2X receptor desensitizing agonist α,β-methylene
ATP (αβm-ATP, 10µM, Table 6). Treatment with the FP receptor
antagonist AL-8810 (5 µM) did not affect baseline responses. In
the presence of AL-8810 increases to baseline tension mediated
by prostaglandin E2 (10 µM) were significantly inhibited both 10
and 20 min after the addition of the agonist (n = 8, p < 0.05 for
both, Figure 4). In the absence of any antagonists, contractions
to PGE2 increased the tension by 233 ± 60% at 10 min. In the
presence of AL-8810 (5 µM) this increase was inhibited with the
remaining contraction of 127± 46% (n = 8, p< 0.05, Table 6).
Prostaglandin F2α on U&LP and Detrusor
Preparations
In preparations of U&LP, treatment with PGF2α (10 µM) caused
a significant increase in the baseline tension of 65 ± 9% (n = 14,
p < 0.001). Additionally, the frequency of spontaneous phasic
contractions increased by 13 ± 5% (n = 14, p < 0.05) with no
changes observed in the amplitude of these contractions. In the
presence of AL-8810 (FP antagonist, 5 µM), increases in the
baseline tension in response to PGF2α (10 µM) were significantly
inhibited (n = 8, p < 0.001, Table 7 and Figure 5). However,
the antagonism of FP receptor did not affect the frequency or
amplitude of spontaneous phasic contractions.
In detrusor preparations, an increase of 88 ± 10% (n = 12,
p < 0.001) was observed in response to PGF2α (10 µM). The
presence of FP antagonist AL-8810 (5µM) significantly inhibited
increases in the baseline tension (n = 8, p< 0.05). The inhibition
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TABLE 4 | U&LP responses to prostaglandin E2 (10 µM) in the absence and presence of atropine (muscarinic antagonist), indomethacin (cyclooxygenase antagonist),
Nω-Nitro-L-arginine (L-NNA, nitric oxide antagonist), α,β-methylene ATP (αβm-ATP, ATP agonist), and AL-8810 (FP antagonist) (mean change ± SEM).
1Tension (g) 1Frequency (cpm)
Antagonist Conc. Absence Presence Absence Presence n
Atropine 1 µM 1.45 ± 0.18 1.55 ± 0.12 0.53 ± 0.18 0.86 ± 0.21 6
Indomethacin 5 µM 1.90 ± 0.25 1.79 ± 0.21 0.73 ± 1.29 2.11 ± 1.45 4
L-NNA 100 µM 2.00 ± 0.32 2.31 ± 0.42 2.86 ± 1.32 3.51 ± 1.78 4
αβm-ATP 10 µM 1.58 ± 0.35 1.99 ± 0.48 0.46 ± 0.22 0.49 ± 0.23 4
AL-8810 5 µM 1.35 ± 0.13 0.93 ± 0.14* 1.12 ± 0.38 0.68 ± 0.27 8
*p < 0.05. Paired Student’s two-tailed t-test.
FIGURE 3 | U&LP responses to PGE2 (10 µM) (A) and in the presence of FP receptor antagonist AL-8810 (5 µM) (B). Increases in the baseline tension in response
to PGE2 are represented as mean change ± SEM (C). Changes in the baseline tension between control and experimental conditions were evaluated using a paired
Student’s two tailed t-test, where *p < 0.05.
TABLE 5 | Detrusor responses to prostaglandin E2 (1 µM) at 10 and 20 min after the addition of agonist in the absence and presence of PGE2 receptor antagonists
(mean change ± SEM).
1Tension (g) at 10 min 1Tension (g) at 20 min
Antagonist Conc. Absence Presence Absence Presence n
SC-19220 10 µM 0.60 ± 0.08 0.49 ± 0.11 1.12 ± 0.18 1.09 ± 0.15 8
AH6809 10 µM 0.64 ± 0.13 0.62 ± 0.10 0.96 ± 0.16 0.95 ± 0.16 8
L-798106 100 nM 1.12 ± 0.20 1.05 ± 1.16 1.25 ± 0.20 1.35 ± 0.26 10
AH23848 10 µM 0.46 ± 0.10 0.49 ± 0.14 0.81 ± 0.16 0.80 ± 0.16 8
None of the antagonists had statistically significant effects (paired Student’s two-tailed t-test).
TABLE 6 | Detrusor responses to prostaglandin E2 (10 µM) in the absence and presence of atropine (muscarinic antagonist), indomethacin (cyclooxygenase antagonist),
Nω-Nitro-L-arginine (L-NNA, nitric oxide antagonist), α,β-methylene ATP (αβm-ATP, ATP agonist), and AL-8810 (FP antagonist) (mean change ± SEM).
1Tension (g) at 10 min 1Tension (g) at 20 min
Antagonist Conc. Absence Presence Absence Presence n
Atropine 1 µM 1.38 ± 0.21 1.02 ± 0.09 1.72 ± 0.11 1.47 ± 0.11 6
Indomethacin 5 µM 1.55 ± 0.55 1.29 ± 0.42 1.75 ± 0.55 1.35 ± 0.43 4
L-NNA 100 µM 2.21 ± 0.28 1.90 ± 0.32 2.05 ± 0.26 1.94 ± 0.27 4
αβm-ATP 10 µM 1.40 ± 0.21 1.72 ± 0.49 1.45 ± 0.29 1.94 ± 0.43 4
AL-8810 5 µM 1.43 ± 0.36 0.84 ± 0.21* 1.39 ± 0.22 1.01 ± 0.18* 8
*p < 0.05. Paired Student’s two-tailed t-test.
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FIGURE 4 | Detrusor responses to PGE2 (10 µM) (A) and in the presence of FP receptor antagonist AL-8810 (5 µM) (B). Increases in the baseline tension in
response to PGE2 are represented as mean change ± SEM (C). Changes in the baseline tension between control and experimental conditions were evaluated using
a paired Student’s two tailed t-test, where *p < 0.05.
was maintained both 10 and 20 min after the addition of PGF2α
(10 µM, Table 7).
DISCUSSION
This study presents prostaglandin E2 as a potential contributor
to the overall urinary bladder contractility and showcases the
ability of isolated urothelium with lamina propria (also called
the bladder mucosa) to respond to this inflammatory mediator.
Prostaglandin E2 causes a baseline tension increase in both
U&LP and detrusor tissue, as well as influences the frequency
and amplitude of U&LP spontaneous phasic contractions. In
addition, this study is the first to identify responses to PGE2
in the urothelium with lamina propria when separated from its
underlying detrusor layer. The two layers are distinct in both
structure and function, with the U&LP comprized of several
layers of epithelial cells and an underlying connective tissue
layer with muscularis mucosae, while the detrusor is composed
primarily of smooth muscle cells. The U&LP not only provides
a physical barrier between urine and the bladder wall but is
TABLE 7 | U&LP responses to PGF2α (10 µM) in the absence and presence of
AL-8810 on the baseline tension and on the frequency and amplitude of phasic
contractions (top).
PGF2α with
PGF2α AL-8810 n
Urothelium with
lamina propria
(U&LP)
1Tension (g) 0.85 ± 0.09 0.49 ± 0.08*** 8
1Amplitude (g) −0.11 ± 0.06 −0.13 ± 0.07 8
1Frequency (cpm) 0.67 ± 0.23 0.73 ± 0.14 8
Detrusor 1Tension (g) at 10 min 0.78 ± 0.18 0.36 ± 0.04* 8
1Tension (g) at 20 min 0.91 ± 0.19 0.57 ± 0.08 8
Detrusor baseline tension responses at 10 and 20 min to PGF2α (10 µM) in
the absence and presence of AL-8810 (bottom). Results represented as mean
change ± SEM. *p < 0.05, ***p < 0.001. Paired Student’s two-tailed t-test.
also capable of releasing chemicals like acetylcholine which can
influence the contractility of the detrusor (Moro et al., 2011).
Furthermore, it is also capable of responding to external signals
like noradrenaline (Moro et al., 2013), nitric oxide (Moro et al.,
2012), the five primary prostaglandins (Stromberga et al., 2020b),
and histamine (Stromberga et al., 2019, 2020a), as well as release
ATP (Andersson et al., 2018). It is known that cells found in
U&LP can express both EP1 and EP2 receptors (Rahnama’i et al.,
2010) indicating that they are capable of responding to PGE2 and
eliciting a contractile response. However, the exact mechanisms
and the involvement of the different PGE2 receptor subtypes in
the contractile responses observed are still unclear.
In this study, increases in the baseline tension in both U&LP
and detrusor tissues that were treated with two concentrations
of PGE2 (1–10 µM) were observed. The presence of PGE2
increased the frequency of spontaneous contractile activity,
which was similar to responses after muscarinic receptor
activation (Moro et al., 2011), the target of many first-
line pharmaceuticals to treat overactive bladder. In detrusor
preparations, which generally do not exhibit spontaneous
phasic contractions, these contractions were initiated in most
preparations in response to the addition of PGE2. Previous
studies have shown that contractions in detrusor smooth muscle
in response to acetylcholine and ATP are enhanced by the
presence of prostaglandins in both rabbit (Anderson, 1982)
and guinea-pig animal models (Nile and Gillespie, 2012). There
are complex interactions between these three molecules, as
ATP enhances PGE2 release via a P2-purinoreceptor-mediated
mechanism (Kasakov and Vlaskovska, 1985) and acetylcholine
release has been detected when unstretched preparations were
exposed to PGE2 (Nile and Gillespie, 2012). Thereby, interactions
between these three mediators can potentially result in the
amplification of molecule signaling and an increase in contractile
activity. However, the involvement of acetylcholine, ATP and
nitric oxide in mediating the increases in both the baseline
tension and the frequency of spontaneous phasic contractions
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FIGURE 5 | U&LP and detrusor responses to PGF2α (10 µM) (A) and in the presence of FP receptor antagonist AL-8810 (5 µM) (B). Increases in the baseline
tension in response to PGF2α are represented as mean change ± SEM (C). Changes in the baseline tension between control and experimental conditions were
evaluated using a paired Student’s two tailed t-test, where *p < 0.05, ***p < 0.001.
were ruled out as the contractile responses were the same when
respective receptors were selectively antagonized or desensitized.
Therefore, even though previous research has shown that
acetylcholine is released when tissue is exposed to PGE2 (Nile
and Gillespie, 2012), the inhibition of muscarinic receptors
revealed no changes in the magnitude of contractions in response
to PGE2. Furthermore, treatment with indomethacin, which
inhibits prostaglandin production via cyclooxygenase (COX), did
not affect contractile responses.
In order to isolate the role of a specific PGE2 receptor
subtype in mediating these changes to baseline tension and
the frequency of spontaneous phasic contractions, selective
receptor antagonists for EP1–EP4 receptors were used. The
antagonists and concentrations selected for this study were based
on prior research investigating smooth muscle contractility in
rat prostate gland (Tokanovic et al., 2010). When U&LP and
detrusor smooth muscle tissues were treated with each individual
PGE2 receptor subtype antagonists (EP1–EP4), there were no
differences observed in the contractile responses to PGE2 when
compared to tissues with no antagonist treatment. Activation
of EP1 and EP3 receptor subtypes mediate contractions in
smooth muscle, whereas EP2 and EP4 are involved in the
relaxatory responses (Woodward et al., 2011). In this study,
when both U&LP and detrusor tissues were treated with the
highly selective EP1 receptor antagonist SC19220 with a pA2
value of approximately 5.9 (Jones et al., 2009) and EP3 receptor
antagonist L798106 with a Ki of 0.3 nM (Juteau et al., 2001)
there was no change in the magnitude of contractions to
PGE2. However, when U&LP was incubated with the EP1-
selective receptor antagonist SC-19220, it took significantly
more time to reach peak contraction in response to PGE2
compared to control tissues. Even though the stimulation
of EP2 receptors has previously been shown to relax non-
vascular urogenital smooth muscle tissue (Coleman et al., 1994;
Tokanovic et al., 2010), no changes in contractile response
were observed in tissue preparations that were treated with
the dual EP1 and EP2 antagonist AH6809 [pA for EP1
approximately 7.3 and pA2 for EP2 approximately 5.7 (Jones
et al., 2009)]. The involvement of EP4 receptors in the
inhibition of muscle contractions was also ruled out using
AH23848, an antagonist for EP4 receptors (pA2 value 5.4)
with no activity on other EP receptor subtypes (Coleman
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et al., 1994). The lack of responses also aligns with previous
findings suggesting that the EP4 receptor is involved in vascular
smooth muscle relaxation instead of smooth muscle of the
urinary bladder (Coleman et al., 1994; Tokanovic et al., 2010).
Findings of this study suggest that the contractile responses
observed to prostaglandin E2 in both U&LP and detrusor may
be mediated by receptors systems other than EP, purinergic
and cholinergic.
The ability of AL-8810 to significantly inhibit the contractile
response to PGE2 suggests a mechanism of action at the FP
receptor. This is most likely a result of the PGE2 chemical
undergoing a conversion from PGE2 into PGF2α through
9-ketoreductase activity upon contact with the tissue. The
potential for these conversions has been known for some
time (Canete Soler et al., 1987; Cheung and Challis, 1989;
Abadir and Siragy, 2015). There is evidence to support a
partial agonist effect of AL-8810 (Griffin et al., 1999). Although
the addition of this antagonist showed no response, or any
effect on the baseline activity. The contraction remaining
after FP receptor inhibition is unknown, although does
not appear to be related to stimulation of the muscarinic,
purinergic or nitric oxide receptor systems, nor from the
creation of new prostaglandins. One potential mechanism of
action could be via a receptor unspecific pathway, such as
affecting calcium channels, and this could be considered for
future experiments.
A limitation of this study was the use of single-dose
applications of PGE2 and PGF2α to examine changes in
frequencies and amplitudes of phasic contractions over a 20-
minute timeframe. It would be of interest to examine a larger
range of concentrations, as well as incorporate alternative
agonists to obtain a wider understanding of the prostaglandin
responses. Finally, there remains no literature showing FP
receptor expression or localization in porcine or any other
animal model bladders, and its identification throughout this
region would assist in a better understanding of this receptor
system. It should also be considered that PGE2 exhibits a
similar affinity to PGF2α on the FP receptor (Abramovitz
et al., 2000), and as such, there is the potential for an
influence of FP receptors in the responses observed. This
cross-sensitivity of FP receptors to PGE2 may also present
a mechanism underlying the inhibitory effect observed from
treatment with AL-8810 and should be further explored in
follow-up studies. Future studies could also investigate whether
the suppressed responses observed after AL-8810 treatment
is due to the actions of PGE2 after a possible conversion
to PGF2α.
This study identifies a functional response in both U&LP and
detrusor preparations to PGE2, and its ability to be inhibited by
an FP receptor antagonist suggests some conversion to PGF2α
upon contact with the tissue. The response of direct application
of PGF2α which appears to be similar to the PGE2 response
also supports this hypothesis. Thereby, the finding of this study
supports and further advances prior research, where PGE2 and
PGF2α had previously been found to contract isolated detrusor
smooth muscle in human preparations (Abrams and Feneley,
1975; Andersson et al., 1977; Palea, 1998).
CONCLUSION
Prostaglandin E2 and prostaglandin F2α can elicit clear
contractile responses in both urinary bladder urothelium with
lamina propria, and detrusor smooth muscle preparations.
Furthermore, the addition of these prostaglandins in U&LP
preparations increases the frequency of spontaneous phasic
contractions. In the detrusor, which normally does not exhibit
spontaneous contractions, these contractions were initiated in
most preparations. The antagonism of all four PGE2 receptor
subtypes, cholinergic receptors and purinergic receptors failed
to inhibit contractile responses observed to the prostaglandins
in either U&LP or detrusor tissues. However, the inhibition of
EP1 receptor in U&LP resulted in a significant decrease in the
time taken to reach peak contractile responses to PGE2 suggesting
partial mediation via the EP1 receptor system. Antagonism of
the FP receptor inhibited responses to PGF2α, but also to PGE2,
suggesting some conversion of this into PGF2α after contact with
the tissue. Overall, contractile responses to both prostaglandin
E2 and prostaglandin F2α appear mediated, in part, by the FP
receptor in both U&LP and detrusor smooth muscle.
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